SCHEMBL3816686

SCHEMBL3816686

Cc1ccccc1CNC(=O)c1ccc(-c2ccnc(N)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.56
ALDH1A1 P00352 2/20 0.56
CA2 P00918 1/20 0.54
BTK Q06187 1/20 0.53
ADORA2A P29274 7/20 0.52
ADORA1 P30542 5/20 0.52
ADORA3 P0DMS8 1/20 0.52
ADORA2B P29275 1/20 0.52
KDM4E B2RXH2 2/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
SCN10A Q9Y5Y9 4/20 0.49
NAMPT P43490 1/20 0.49
TAOK1 Q7L7X3 1/20 0.49
TAOK3 Q9H2K8 1/20 0.49
SCN2A Q99250 3/20 0.48
PPARG P37231 1/20 0.47
AURKA O14965 1/20 0.46
HSP90AA1 P07900 1/20 0.46
PRKACA P17612 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3818520 0.90 CYP3A4 (0.49) CA2BTKADORA2AADORA1LMNA
SCHEMBL14009836 0.88 HPGD (0.59) HPGDALDH1A1CA2KDM4ELMNA
SCHEMBL3815220 0.86 ROCK1 (0.52) HPGDADORA2AADORA1ADORA3ADORA2B
SCHEMBL3818878 0.86 SMN1; SMN2 (0.62) HPGDADORA2AADORA1ADORA3ADORA2B
SCHEMBL3818546 0.86 HTT (0.64) HPGDALDH1A1ADORA2AADORA1ADORA3
SCHEMBL3816956 0.83 MAPK1 (0.62) HPGDCA2ADORA2AAURKAHSP90AA1
SCHEMBL14009848 0.83 CYP3A4 (0.47) HPGDALDH1A1CA2KDM4ELMNA
SCHEMBL3819783 0.81 MMP13 (0.61) CA2ADORA2ALMNAAURKAHSP90AA1
SCHEMBL4923587 0.80 AKT3 (0.55) HPGDALDH1A1BTKADORA2AADORA1
SCHEMBL14021121 0.79 CAMK2D (0.55) HPGDALDH1A1BTKSCN10ASCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713775-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-08-12 EP claimed
US-20080275062-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-11-06 US claimed
EP-1713775-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-25 EP claimed
WO-2005074643-A2 BENZAMIDE COMPOUNDS USEFUL AS ROCK INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-18 WO claimed
EP-1713775-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-08-12 EP disclosed
US-20080275062-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-11-06 US disclosed
EP-1713775-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-25 EP disclosed
WO-2005074643-A2 BENZAMIDE COMPOUNDS USEFUL AS ROCK INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275062-A1 Chemical Compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 HPGD 647/4885ALDH1A1 1941/4885CA2 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.